Kose Sukran, Gurkan Alp, Akman Fatih, Kelesoglu Mehmet, Uner Ufuk
Clinical Microbiology and Infectious Diseases Clinic, Izmir Tepecik Training and Research Hospital, Izmir, Turkey.
J Gastroenterol. 2009;44(4):353-8. doi: 10.1007/s00535-009-0016-z. Epub 2009 Mar 11.
Hepatitis C virus (HCV) is prevalent in renal insufficient patients. The aim of the present study was to evaluate the efficacy and tolerability of pegylated interferon alpha-2a (peg-IFN-alpha-2a) among these patients.
Among 437 patients within total hemodialysis population in hemodialysis units, in total 83 patients (19.0%) were anti-HCV positive and of these 83 patients, 33 (39.7%) were HCV-RNA positive. Treatment was initiated in 33 patients who had chronic HCV infection. All patients were found to be HCV-RNA positive. During treatment, peg-IFN-alpha-2a (40 kDa), 135 microg/week was used on these 33 patients.
Twenty-six (78.8%) of the 33 patients enrolled in the study completed the treatment. Two patients (6.0%) did not complete treatment because they had serious adverse events such as anemia and thrombocytopenia. At the onset of treatment, while all of 26 patients were HCV RNA positive, HCV RNA turned to negative in all 26 patients 3 months after treatment.
At the end of the study, peg-IFN-alpha-2a treatment of patients with chronic hepatitis C on maintenance hemodialysis may improve prognosis and their quality of life.
丙型肝炎病毒（HCV）在肾功能不全患者中普遍存在。本研究的目的是评估聚乙二醇化干扰素α-2a（peg-IFN-α-2a）在这些患者中的疗效和耐受性。
在血液透析单位的437例血液透析患者中，共有83例（19.0%）抗HCV阳性，在这83例患者中，33例（39.7%）HCV-RNA阳性。33例慢性HCV感染患者开始治疗。所有患者均被发现HCV-RNA阳性。治疗期间，对这33例患者使用聚乙二醇化干扰素α-2a（40 kDa），135μg/周。
纳入研究的33例患者中有26例（78.8%）完成了治疗。2例患者（6.0%）因出现贫血和血小板减少等严重不良事件而未完成治疗。治疗开始时，26例患者HCV RNA均为阳性，治疗3个月后所有26例患者HCV RNA均转为阴性。
在研究结束时，对维持性血液透析的慢性丙型肝炎患者使用聚乙二醇化干扰素α-2a治疗可能改善预后及其生活质量。
